Roche will pay $114.50 per share, more than twice Spark’s closing price on Feb. 22.
The deal will give Roche access to a gene therapy for blindness priced at $850,000 per patient, as well as other projects for hemophilia and neurodegenerative disorders like Huntington’s disease.
Roche’s deal comes as other big-name drugmakers pivot to gene therapy.
Read the full report here.
More articles on pharmacy:
5 recent pharma bankruptcies
Top 10 fatal or harmful prescribing errors
Civica Rx will start as middleman for drugmakers, hospitals, Bloomberg says
